Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemias

• Published in: Clinical and translational medicine Vol. 12; no. 6; pp. e933 - n/a
• Main Authors: Cantilena, Sandra, Gasparoli, Luca, Pal, Deepali, Heidenreich, Olaf, Klusmann, Jan‐Henning, Martens, Joost H. A., Faille, Alexandre, Warren, Alan J., Karsa, Mawar, Pandher, Ruby, Somers, Klaartje, Williams, Owen, de Boer, Jasper
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.06.2022; John Wiley and Sons Inc; Wiley
• Subjects: Acute Disease; Apoptosis; Bioluminescence; Cell Proliferation; Chemotherapy; Child; Chromosomes; Clinical medicine; Cloning; Epigenesis, Genetic; Flow cytometry; Gene expression; Humans; Infant; leukaemia; Leukemia; Leukemia - genetics; Medical prognosis; MLL‐fusion; mouse models; Oncogene Proteins, Fusion - genetics; Oncogene Proteins, Fusion - metabolism; precision medicine; Proteins; targeted therapy; mouse models; targeted therapy; leukaemia; precision medicine; MLL-fusion

Background Improving the poor prognosis of infant leukaemias remains an unmet clinical need. This disease is a prototypical fusion oncoprotein‐driven paediatric cancer, with MLL (KMT2A)‐fusions present in most cases. Direct targeting of these driving oncoproteins represents a unique therapeutic oppo...